|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: GLOBOCAN 2008. Cancer Incidence and
Mortality Worldwide: IARC CancerBase No. 10 [Internet].
International Agency for Research on Cancer; Lyon, France: 2010,
[http://globocan.iarc.fr].
|
|
2
|
Marin JJ, Romero MR and Briz O: Molecular
bases of liver cancer refractoriness to pharmacological treatment.
Curr Med Chem. 17:709–740. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu AX: Systemic therapy of advanced
hepatocellular carcinoma: how hopeful should we be? Oncologist.
11:790–800. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thomas MB, O’Beirne JP, Furuse J, Chan AT,
Abou-Alfa G and Johnson P: Systemic therapy for hepatocellular
carcinoma: cytotoxic chemotherapy, targeted therapy and
immunotherapy. Ann Surg Oncol. 15:1008–1014. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim JH, Chung JB, Park IS, et al: Combined
use of tamoxifen, cyclosporin A, and verapamil for modulating
multidrug resistance in human hepatocellular carcinoma cell lines.
Yonsei Med J. 34:35–44. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferry DR, Traunecker H and Kerr DJ:
Clinical trials of P-glycoprotein reversal in solid tumours. Eur J
Cancer. 32A:1070–1081. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thomas H and Coley HM: Overcoming
multidrug resistance in cancer: an update on the clinical strategy
of inhibiting p-glycoprotein. Cancer Control. 10:159–165.
2003.PubMed/NCBI
|
|
8
|
Meng Z, Yang P, Shen Y, et al: Pilot study
of huachansu in patients with hepatocellular carcinoma,
non-small-cell lung cancer, or pancreatic cancer. Cancer.
115:5309–5318. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang LS, Nakaya K, Yoshida T and Kuroiwa
Y: Bufalin as a potent inducer of differentiation of human myeloid
leukemia cells. Biochem Biophys Res Commun. 178:686–693. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Watabe M, Ito K, Masuda Y, Nakajo S and
Nakaya K: Activation of AP-1 is required for bufalin-induced
apoptosis in human leukemia U937 cells. Oncogene. 16:779–787. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yeh JY, Huang WJ, Kan SF and Wang PS:
Effects of bufalin and cinobufagin on the proliferation of
androgen-dependent and -independent prostate cancer cells.
Prostate. 54:112–124. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li D, Qu X, Hou K, et al: PI3K/Akt is
involved in bufalin-induced apoptosis in gastric cancer cells.
Anticancer Drugs. 20:59–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han KQ, Huang G, Gu W, Su YH, Huang XQ and
Ling CQ: Anti-tumor activities and apoptosis-regulated mechanisms
of bufalin on the orthotopic transplantation tumor model of human
hepatocellular carcinoma in nude mice. World J Gastroenterol.
13:3374–3379. 2007.
|
|
14
|
Gu W, Fang FF, Li B, Cheng BB and Ling CQ:
Characterization and resistance mechanisms of a
5-fluorouracil-resistant hepatocellular carcinoma cell line. Asian
Pac J Cancer Prev. 13:4807–4814. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi LX, Ma R, Lu R, et al: Reversal effect
of tyroservatide (YSV) tripeptide on multi-drug resistance in
resistant human hepatocellular carcinoma cell line BEL-7402/5-FU.
Cancer Lett. 269:101–110. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Robert J and Jarry C: Multidrug resistance
reversal agents. J Med Chem. 46:4805–4817. 2003. View Article : Google Scholar
|
|
17
|
Ramachandran C, Rabi T, Fonseca HB,
Melnick SJ and Escalon EA: Novel plant triterpenoid drug amooranin
overcomes multidrug resistance in human leukemia and colon
carcinoma cell lines. Int J Cancer. 105:784–789. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ravizza R, Gariboldi MB, Molteni R and
Monti E: Linalool, a plant-derived monoterpene alcohol, reverses
doxorubicin resistance in human breast adenocarcinoma cells. Oncol
Rep. 20:625–630. 2008.PubMed/NCBI
|
|
19
|
Xu M, Sheng LH, Zhu XH, Zeng SB and Zhang
GJ: Reversal effect of Stephania tetrandra-containing Chinese herb
formula SENL on multidrug resistance in lung cancer cell line
SW1573/2R120. Am J Chin Med. 38:401–413. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Han Y, Bu LM, Ji X, Liu CY and Wang ZH:
Modulation of multidrug resistance by andrographolid in a
HCT-8/5-FU multidrug-resistant colorectal cancer cell line.
Chin J Dig Dis. 6:82–86. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Borska S, Sopel M, Chmielewska M, Zabel M
and Dziegiel P: Quercetin as a potential modulator of
P-glycoprotein expression and function in cells of human pancreatic
carcinoma line resistant to daunorubicin. Molecules. 15:857–870.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang PM, Chan JY, Zhang DM, et al:
Pheophorbide a, an active component in Scutellaria barbata,
reverses P-glycoprotein-mediated multidrug resistance on a human
hepatoma cell line R-HepG2. Cancer Biol Ther. 6:504–509. 2007.
|
|
23
|
Sun BT, Zheng LH, Bao YL, Yu CL, Wu Y,
Meng XY and Li YX: Reversal effect of Dioscin on multidrug
resistance in human hepatoma HepG2/adriamycin cells. Eur J
Pharmacol. 654:129–134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang M, Jin J, Sun H and Liu GT: Reversal
of P-glycoprotein-mediated multidrug resistance of cancer cells by
five schizandrins isolated from the Chinese herb Fructus
Schizandrae. Cancer Chemother Pharmacol. 62:1015–1026. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fong WF, Wan CK, Zhu GY, Chattopadhyay A,
Dey S, Zhao Z and Shen XL: Schisandrol A from Schisandra
chinensis reverses P-glycoprotein-mediated multidrug resistance
by affecting Pgp-substrate complexes. Planta Med. 73:212–220.
2007.
|
|
26
|
Yu CH, Kan SF, Pu HF, Jea Chien E and Wang
PS: Apoptotic signaling in bufalin-and cinobufagin-treated
androgen-dependent and -independent human prostate cancer cells.
Cancer Sci. 99:2467–2476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hong SH and Choi YH: Bufalin induces
apoptosis through activation of both the intrinsic and extrinsic
pathways in human bladder cancer cells. Oncol Rep. 27:114–120.
2012.PubMed/NCBI
|
|
28
|
Yin JQ, Shen JN, Su WW, et al: Bufalin
induces apoptosis in human osteosarcoma U-2OS and U-2OS
methotrexate 300-resistant cell lines. Acta Pharmacol Sin.
28:712–720. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Takai N, Ueda T, Ishii T, et al: Effects
of bufalin on the proliferation of human choriocarcinoma cells. Int
J Gynecol Cancer. 21:1105–1109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Takai N, Ueda T, Nishida M, Nasu K and
Narahara H: Bufalin induces growth inhibition, cell cycle arrest
and apoptosis in human endometrial and ovarian cancer cells. Int J
Mol Med. 21:637–643. 2008.PubMed/NCBI
|
|
31
|
Xie CM, Chan WY, Yu S, Zhao J and Cheng
CH: Bufalin induces autophagy-mediated cell death in human colon
cancer cells through reactive oxygen species generation and JNK
activation. Free Radic Biol Med. 51:1365–1375. 2011. View Article : Google Scholar
|
|
32
|
Nasu K, Nishida M, Ueda T, Takai N, Bing
S, Narahara H and Miyakawa I: Bufalin induces apoptosis and the
G0/G1 cell cycle arrest of endometriotic stromal cells: a promising
agent for the treatment of endometriosis. Mol Hum Reprod.
11:817–823. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jing Y, Watabe M, Hashimoto S, Nakajo S
and Nakaya K: Cell cycle arrest and protein kinase modulating
effect of bufalin on human leukemia ML1 cells. Anticancer Res.
14:1193–1198. 1994.PubMed/NCBI
|
|
34
|
Watabe M, Masuda Y, Nakajo S, Yoshida T,
Kuroiwa Y and Nakaya K: The cooperative interaction of two
different signaling pathways in response to bufalin induces
apoptosis in human leukemia U937 cells. J Biol Chem.
271:14067–14072. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qi F, Inagaki Y, Gao B, et al: Bufalin and
cinobufagin induce apoptosis of human hepatocellular carcinoma
cells via Fas- and mitochondria-mediated pathways. Cancer Sci.
102:951–958. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang N, Yin Y, Xu SJ and Chen WS:
5-Fluorouracil: mechanisms of resistance and reversal strategies.
Molecules. 13:1551–1569. 2008. View Article : Google Scholar : PubMed/NCBI
|
